Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

+1.42 (+1.02%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.34B
Current PE48.96
Forward PE 23.71
2yr Forward PE 34.98
See more stats
Estimates Current Quarter
Revenue$56.26 Million
Adjusted EPS$1.07
See more estimates
10-Day MA$138.94
50-Day MA$122.75
200-Day MA$133.30
See more pivots

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B Stock, NASDAQ:LGND

3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121
United States of America
Phone: +1.858.550.7500
Number of Employees: 155


Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.